[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia

Table 4

Comparison of indicators in the use of rhTPO for treatment of grade II and III thrombocytopenia [n, (%)].

Indicators	Use of recombinant human thrombopoietin (rhTPO)		Z/χ^2 value	P Value
	Grade II (n = 100)	Grade III (n = 94)
Days of treatment	5.00 (3.00, 6.00)	6.00 (4.00, 8.00)	−3.610	<0.001
Time to increase platelets (days)	3.00 (2.00, 5.00)	5.50 (3.00, 8.00)	−4.977	<0.001
Delay of the next chemoradiotherapy cycle (days)	0 (0, 5.75)	3.00 (0, 9.25)	−2.602	0.009
Prolonged hospitalization due to platelet decline (days)	1.00 (0, 6.00)	3.50 (0, 7.00)	−1.821	0.069
Increased hospitalization costs due to platelet decline	5040.00 (3024.00, 6979.00)	6503.00 (5040.00, 9474.00)	−4.900	<0.001
Platelet transfusion
No	95 (95.0)	67 (71.3)	19.798	<0.001
Yes	5 (5.0)	27 (28.7)